Profiles of COURAGE: Another Speed Bump for Stents or Flawed Trial?

Cardiologists and interventionalists continue to disagree on the importance of the COURAGE trial results. Academic disputes aside, the question for industry is whether this study will further drive down stent usage.

by Stephen Levin

In this era of evidence-based medicine with its abundance of clinical trials, particularly in cardiology, it’s hard to recall a...

More from Innovation

More from In Vivo

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By 

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.